Selective progesterone receptor modulators (SPRMs) are a new class of compounds
developed to target the progesterone receptor (PR) with a mix of agonist and antagonist …

Context Mifepristone (RU 486) blocks the action of cortisol by binding to the glucocorticoid
receptor and, therefore, is of potential therapeutic value in Cushing's syndrome. However …

BACKGROUND: The aims of the present study were to examine whether periovulatory
administration of a cyclo-oxygenase (COX)-2 inhibitor affects human ovulation and …

The potentiality of mifepristone as an abortifacient and contraceptive drug along with its
pharmacokinetic parameters is reviewed. Mifepristone or RU486 acts as antagonist to …

Mifepristone is a steroidal antiprogestin and antiglucocorticoid acting at the receptor level.
The aromatic dimethylaminophenyl side chain in position 11 of the steroid structure is …

Roussel Uclaf in partnership with the INSERM unit of Prof. EE Baulieu first discovered
mifepristone (RU486) as part of a large research program on steroidal compounds with …

The pharmacokinetics of mifepristone is characterized by rapid absorption, a long half-life of
25–30 h, and high micromolar serum concentrations following ingestion of doses of≥ 100 …

Cancer rates are set to increase at an alarming rate, from 10 million new cases globally in
2000 to 15 million in 2020. Regarding the pharmacological treatment of cancer, we currently …

In addition to its well-known abortifacient effect, mifepristone (MIF) has been used as an
anticancer drug for various cancers in many studies with an in-depth understanding of the …

The objective of this study was to prepare an oral dosage formulation of mifepristone that will
improve the oral bioavailability of mifepristone and sustain the release of mifepristone for at …